-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Program: Education Program
Session: CAR T Cells in ALL: Bridge or Definitive Therapy?
Hematology Disease Topics & Pathways:
Biological therapies, Clinical Practice (Health Services and Quality), Chimeric Antigen Receptor (CAR)-T Cell Therapies, pediatric, Therapies, Adverse Events, Study Population, Human
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Nirali N. Shah, M.D.

Pediatric Oncology Branch, National Institutes of Health, Bethesda, MD

Disclosures: Shah: CARGO: Consultancy; Lentigen: Research Funding; VOR: Consultancy, Research Funding; Immunoadoptive Cell Therapy Private Limited: Consultancy, Other: Scientific Advisory Board.

See more of: CAR T Cells in ALL: Bridge or Definitive Therapy?
See more of: Education Program
Previous Presentation | Next Presentation >>